RT Journal Article SR Electronic T1 Extracorporeal Blood Purification in moderate and severe COVID-19 patients: a prospective cohort study JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.10.10.20210096 DO 10.1101/2020.10.10.20210096 A1 Rodney Alexander Rosalia A1 Petar Ugurov A1 Dashurie Neziri A1 Simona Despotovska A1 Emilja Kostoska A1 Lidija Veljanovska-Kiridjievska A1 Dimche Kuzmanov A1 Aleksandar Trifunovski A1 Gianluca Villa A1 Dijana Popevski A1 Zan Mitrev YR 2020 UL http://medrxiv.org/content/early/2020/10/13/2020.10.10.20210096.abstract AB Introduction COVID-19 is characterised by hyperinflammation and coagulopathy. Severe cases often develop respiratory distress, requiring mechanical ventilation and critical cases progressing to ARDS. Control of hyperinflammation has been proposed as a possible therapeutic avenue for COVID-19; extracorporeal blood purification (EBP) modalities offer an attractive mean to ameliorate maladaptive inflammation.With this work, we describe the longitudinal variation of parameters of systemic inflammation in critically ill COVID-19 patients treated with blood purification using AN69ST (oXiris®) hemodiafilter.Methods We performed a time-series analysis of 44 consecutive COVID-19 cases treated with the AN69ST (oXiris®) cytokine adsorbing hemodiafilter; we visualise longitudinal results of biochemical, inflammatory, blood gas- and vital sign parameters.Results Blood purification was indicated for suspected hyperinflammation or hypercoagulation, (= CRP ≥ 100 mg/L and/or IL-6 ≥ 40 pg/mL and/or Ferritin ≥ 500 ng/mL and/or Lactate Dehydrogenase > 365 U/L or D-dimers > 2000 ng/mL). All patients were treated with ≥ 1 cycle extracorporeal continuous venovenous hemofiltration (CVVHF) with cytokine adsorbing hemodiafilter (CAH); of these, 30 severe patients received CVVHF-CAH within 4 – 12 hours of hospitalisation. Another 14 patients admitted with mild-to-moderate symptoms progressed to severe disease and placed on EBP during the course of hospitalisation. The treatment was associated with a reduction of Ferritin, C-reactive protein, Fibrinogen, several inflammatory markers and a resolution of numerous cytopenias. The observed mortality across the cohort was 36.3% across the cohort.Conclusion Extracorporeal blood purification with cytokine adsorbing hemofilter was associated with a decrease in the acute phase proteins CRP, Ferritin, and resolution of numerous cytopenias. Repetitive hemofiltration has been associated with lower levels of IL-6 in COVID-19 patients.Competing Interest StatementDr Zan Mitrev is the hospital director at the Zan Mitrev Clinic. Gianluca Villa has received support for travel expenses, hotel accommodations and registration to meetings from Baxter. The other co-authors do not have any competing interests to disclose.Clinical TrialNCT04478539Funding StatementNot applicableAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The local ethical committee of the Zan Mitrev Clinic reviewed and approved the clinical practice, treatment procedures described, and the results reported in this manuscript and approved the submission, #EBPZ.357. Trial registration: ClinicalTrials.gov, NCT04478539. Registered 14th of July 2020 - Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT04478539 Written informed (or temporary verbal) consent was obtained from all patients for publication of this manuscript and any accompanying images; the use of all health and medical information for scientific research and manuscript preparation was approved. A copy of the written consent is available for review by the Editor-in-Chief of this journal. For those patients that were not traceable after discharge, the need for informed consent was waived by the ethical committee. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used for this study are currently in transfer in the SCCM COVID-19 registry, https://sccmcovid19.org/. Until upload is completed the data is available for review upon reasonable request by editorial staff members.ILinterleukinTNFtumor necrosis factorCRPC-reactive proteinARDSacute respiratory distress syndromeAKIAcute Kidney InjuryCPAPContinuous Positive Airway PressureEBPExtracorporeal Blood PurificationCVVHcontinuous venovenous hemofiltrationCVVHDFcontinuous venovenous hemodiafiltrationSCUFslow continuous ultrafiltrationNIVNon-invasive ventilation